The iQ Group Global Revenue and Competitors

Claim your profile

Sydney, AUS

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • The iQ Group Global's estimated annual revenue is currently $7.4M per year.(i)
  • The iQ Group Global's estimated revenue per employee is $155,000

Employee Data

  • The iQ Group Global has 48 Employees.(i)
  • The iQ Group Global grew their employee count by -33% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$231M149047%N/AN/A
#2
$7.4M48-33%N/AN/A
#3
N/A560%$106.1MN/A
#4
$7.6M49N/AN/AN/A

The iQ Group Global provides a turnkey solution for life sciences companies, spanning corporate advisory and investment banking, through to research, development, commercialization and sales. The Group facilitates an end to end solution along the drug lifecycle creating the medicines of tomorrow. Our life science and pharmaceutical business unit collaborates with scientists the world over: identifying and owning Intellectual Property, creating and executing drug development plans from discovery to market. In addition, our dedicated investment banking business transforms biotech from an alternative investment option to a requisite mainstream capital market asset. We design and market innovative structured financial products and solutions. These provide entry and exit, investment and divestment, in the 12 or more-year drug development cycle. In this way, The iQ Group Global is bridging capital with science to create the medicines of the future. The iQ Group Global consists of the following: iQnovate Ltd (IQN: NSX) Bridging science with business iQ3Corp. Ltd (iQ3: ASX) Translating science into capital and beyond iQX Investments Ltd (iQX: NSX) Eradicating disease through capital investment iQDex iQDex Life Sciences Index Clinical Research Corporation (CRC) Pty Ltd Redefining Medical Affairs FarmaForce Ltd (FFC:ASX) Shaping the future, together iQ Capital Inc Our New York-based investment bank, investing in the medicines of the future iQBiosensor Saliva: The future of glucose monitoring Capital Labs A new era in startup venture funding

keywords:N/A

N/A

Total Funding

48

Number of Employees

$7.4M

Revenue (est)

-33%

Employee Growth %

N/A

Valuation

N/A

Accelerator

The iQ Group Global News

2021-07-09 - iQ Global : GBS awarded $6.3 million Federal Government science grant to manufacture biosensor technology.

9 July 2021 Announcements National Stock Exchange of Australia 1 Bligh St Sydney NSW 2000 Market announcement - GBS awarded $6.3 million Federal Government science grant to manufacture biosensor technology The iQ Group Global Ltd (NSX.IQG), on behalf of its portfolio company, GBS (Nasdaq: ...

2021-08-11 - How medical research and innovation is transformed into commercially viable products

Image: the Saliva Glucose Biosensor, the first non-invasive, pain-free replacement for finger-prick glucose testing for people living with diabetes. This article is sponsored by The iQ Group Global. What if we could create a world free of disease? That’s the only question on the mind of The iQ ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.1M480%N/A
#2
$5.6M48-4%N/A
#3
$9.6M4812%N/A
#4
$9.6M484%N/A
#5
$5.8M484%N/A